Dare Bioscience Files 8-K on Financials
Ticker: DARE · Form: 8-K · Filed: May 13, 2025 · CIK: 1401914
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Dare Bioscience dropped an 8-K, mostly standard financial updates.
AI Summary
On May 13, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Dare Bioscience is providing updates on its financial status and operational results to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial condition and results of operations, with no immediate indication of significant positive or negative developments.
Key Players & Entities
- Dare Bioscience, Inc. (company) — Registrant
- Cerulean Pharma Inc. (company) — Former Company Name
- Tempo Pharmaceuticals Inc (company) — Former Company Name
- May 13, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Dare Bioscience, Inc.?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 13, 2025.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Dare Bioscience, Inc.
What is the principal executive office address for Dare Bioscience, Inc.?
The principal executive office address is 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
What were Dare Bioscience, Inc.'s former company names?
Dare Bioscience, Inc.'s former company names were Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 13, 2025 regarding Dare Bioscience, Inc. (DARE).